MFG
ONCY

Magnus Financial Group’s Oncolytics Biotech ONCY Stock Holding History

Magnus Financial Group’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-25,000
Closed -$14K – 616
2019
Q3 		$14K Buy
25,000
+15,000
+150% +$15.3K ﹤0.01% 539
2019
Q2 		$17K Buy
+10,000
New +$18.1K ﹤0.01% 539

Other funds holding ONCY

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CGA
Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Magnus Financial Group's ONCY Position: Q4 2019 in Review

Magnus Financial Group sold out of Oncolytics Biotech (ONCY) in Q4 2019, closing a stake of 25,000 shares — an estimated $14K sold.

Magnus Financial Group first reported a position in ONCY in Q2 2019 and held it in 2 quarters. The position peaked at $17K in Q2 2019. 28 funds tracked by Wall St. Rank hold ONCY as of Q4 2019.

  • Magnus Financial Group reported no remaining Oncolytics Biotech position as of Q4 2019 after selling out during the quarter.
  • Magnus Financial Group sold 25,000 Oncolytics Biotech shares in Q4 2019, an estimated $14K.
  • Magnus Financial Group first reported a position in Oncolytics Biotech in Q2 2019 and held it in 2 quarters.
  • Magnus Financial Group's Oncolytics Biotech position peaked at $17K in Q2 2019.
  • 28 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2019.

Based on Magnus Financial Group's 13F filing for Q4 2019, filed 28 Jan 2020.